COMMUNIQUÉS West-GlobeNewswire

Basel Medical Group Ltd (BMGL) Prices Registered Direct Offering
08/10/2026
Singapore, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today entered into a placement agency agreement with Cathay Securities, Inc., as the placement agent (the “Placement [...]
Vascudyne’s Lab-Grown Vessel Passes the Two-Year Mark Supplying Blood to a Patient’s Heart as a Coronary Bypass
08/10/2026
Two-year clinical follow-up presented at EACTS 2026, highlighting the potential of Vascudyne’s bioengineered platform technology BARCELONA, Spain and ST. PAUL, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Vascudyne, Inc., a [...]
Procedure of the Annual General Meeting
08/10/2026
ANNOUNCEMENT NO. 319 8 October 2026 The Annual General Meeting of ChemoMetec A/S was held on 8 October 2026 at 17:30 at Nordsjællands KonferenceCenter. At the Annual General Meeting, the Board of Directors' report on [...]
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
08/10/2026
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to [...]
Echosens to Address GLP-1 Costs and Metabolic Health at SIIA National Conference 2026, Highlight Opportunities for Self-Insured Stakeholders and On-Site Clinics
08/10/2026
WESTBOROUGH, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Echosens , a global leader in non-invasive liver diagnostics and maker of FibroScan®, announces that Shawn McGinnis, Director, Health Systems and Employer Markets, [...]
Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies
08/10/2026
Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Life Biosciences (“Life Bio”), a [...]
UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
08/10/2026
WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN ), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to [...]
XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
08/10/2026
● Clinical Trial Application planned for filing with Health Canada, extending the Company’s international regulatory strategy for gout program XRx-026 ● CALGARY, Alberta, Oct. 08, 2026 (GLOBE NEWSWIRE) -- XORTX [...]
Lakefront Receives Transparency Notification from Bank of America
08/10/2026
Mechelen, Belgium; October 8, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to Belgian [...]
Sienna Continues Platform Growth in Ontario
08/10/2026
MARKHAM, Ontario, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has entered into a purchase agreement to acquire Brighton Retirement [...]
Alamar Biosciences to Report Third Quarter 2026 Financial Results on November 3, 2026
08/10/2026
FREMONT, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced it will report [...]
Quantum-Si Demonstrates Detection of 19 Amino Acids in Proteus™ Development Program
08/10/2026
Company is working to deploy 19-amino-acid detection into a developmental sequencing kit and remains confident in demonstrating detection of all 20 amino acids by year-end 2026 BRANFORD, Conn., Oct. 08, 2026 (GLOBE [...]
NovaBridge Biosciences Announces Expanded Givastomig Safety and Efficacy Data to be Presented at the European Society for Medical Oncology 2026
08/10/2026
ROCKVILLE, Md., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ: NBP) today announced that updated results from the Phase 1b combination study of givastomig, a Claudin 18.2 (CLDN18.2) x 4-1BB bispecific [...]
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
08/10/2026
-- Open-Label Extension (OLE) Data of STENOVA Phase 2a study with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) selected for oral presentation at UEG Week 2026 -- -- Results support initiation of global NOV-ERA [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
08/10/2026
ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a member of the Company’s Executive Committee and Board of Directors. [...]
AnewHealth Names Nationally Recognized Geriatrician and PACE Leader Dr. James Mittelberger Chief Medical Officer
08/10/2026
With decades of experience advancing care for older adults and people with complex medical needs, Dr. Mittelberger will help lead AnewHealth’s clinical strategy and continued innovation in medication management and [...]
New results across pediatric, adult and real-world insomnia settings highlight the expanding clinical evidence for daridorexant at Sleep Europe 2026
08/10/2026
Phase 2 results with daridorexant in pediatric insomnia disorder will be presented in a late-breaking "Impactful Clinical Trial" session. These are the first and only investigational data of a dual orexin receptor [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2026
08/10/2026
Nombre total de droits de vote et d’actions composant le capital social au 30 septembre 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of September 30, 2026
08/10/2026
Disclosure of Share Capital and Voting Rights Outstanding as of September 30, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]

Pages